The progress of therapeutic vaccination with regard to tuberculosis

Research output: Contribution to journalReview articleResearchpeer-review

36 Citations (Scopus)


© 2016 Cardona. A major problem with tuberculosis (TB) control is the long duration of drug therapy-both for latent and for active TB. Therapeutic vaccination has been postulated to improve this situation, and to this end there are several candidates already in clinical phases of development. These candidates follow two main designs, namely bacilli-directed therapy based on inactivated -whole or -fragmented bacillus (Mycobacterium w and RUTI) or fusion proteins that integrate non-replicating bacilli -related antigens (H56 vaccine), and host-directed therapy to reduce the tissue destruction. The administration of inactivated Mycobacterium vaccae prevents the "Koch phenomenon" response, and oral administration of heat-killed Mycobacterium manresensis prevents excessive neutrophilic infiltration of the lesions. This review also tries to explain the success of Mycobacterium tuberculosis by reviewing its evolution from infection to disease, and highlights the lack of a definitive understanding of the natural history of TB pathology and the need to improve our knowledge on TB immunology and pathogenesis.
Original languageEnglish
Article number1536
JournalFrontiers in Microbiology
Issue numberSEP
Publication statusPublished - 28 Sep 2016


  • H56
  • Mycobacterium indicus pranii
  • Mycobacterium manresensis
  • Mycobacterium tuberculosis
  • Mycobacterium vaccae
  • Mycobacterium w
  • Neutrophils
  • Vaccines


Dive into the research topics of 'The progress of therapeutic vaccination with regard to tuberculosis'. Together they form a unique fingerprint.

Cite this